Original research

Cardiovascular disease and mortality sequelae of COVID-19 in the UK Biobank

Zahra Raisi-Estabragh1,2, Jackie Cooper1, Ahmed Salih1, Betty Raman3, Aaron Mark Lee1, Stefan Neubauer3, Nicholas C. Harvey4,5, Steffen E. Petersen1,2,6,7

ABSTRACT

Objective To examine association of COVID-19 with incident cardiovascular events in 17 871 UK Biobank cases between March 2020 and 2021.

Methods COVID-19 cases were defined using health record linkage. Each case was propensity score-matched to two uninfected controls on age, sex, deprivation, body mass index, ethnicity, diabetes, prevalent ischaemic heart disease (IHD), smoking, hypertension and high cholesterol. We included the following incident outcomes: myocardial infarction, stroke, heart failure, atrial fibrillation, venous thromboembolism (VTE), pericarditis, all-cause death, cardiovascular death, IHD death. Cox proportional hazards regression was used to estimate associations of COVID-19 with each outcome over an average of 141 days (range 32–395) of prospective follow-up.

Results Non-hospitalised cases (n=14 304) had increased risk of incident VTE (HR 2.74 (95% CI 1.38 to 5.45); p<0.004) and death (HR 10.23 (95% CI 7.63 to 13.70); p<0.0001). Individuals with primary COVID-19 hospitalisation (n=2 701) had increased risk of all outcomes considered. The largest effect sizes were with VTE (HR 27.6 (95% CI 14.5 to 52.3); p<0.0001), heart failure (HR 21.6 (95% CI 10.9 to 42.9); p<0.0001) and stroke (HR 17.5 (95% CI 5.26 to 57.9); p<0.0001). Those hospitalised with COVID-19 as a secondary diagnosis (n=866) had similarly increased cardiovascular risk. The associated risks were greatest in the first 30 days after infection but remained higher than controls even after this period.

Conclusions Individuals hospitalised with COVID-19 have increased risk of incident cardiovascular events across a range of disease and mortality outcomes. The risk of most events is highest in the early postinfection period. Individuals not requiring hospitalisation have increased risk of VTE, but not of other cardiovascular-specific outcomes.

INTRODUCTION

COVID-19 has emerged as a major cause of morbidity and mortality worldwide. Several studies have linked exposure to COVID-19 with higher risk of adverse cardiovascular outcomes, even after recovery from the acute illness.1,2 Given the high population exposure to COVID-19, these reports may herald a significant imminent public health problem.

There is urgent need to better understand the long-term cardiovascular consequences of COVID-19. However, existing evidence is mostly limited to retrospective studies, includes only a narrow selection of cardiovascular outcomes and lacks adequate consideration of differential risk by COVID-19 severity.1,2 It is important to understand whether the augmented cardiovascular risk associated with COVID-19 is limited to those with severe disease or extends to the wider population of individuals with mild manifestations. This information would define the magnitude of any potential public health impact and guide appropriate targeting of healthcare strategies.

We examined associations of COVID-19 exposure with incident cardiovascular disease (CVD)
and mortality outcomes in 17,871 UK Biobank cases, independent of shared risk factors and considered differential relationships by severity of COVID-19.

METHODS

Study population

The UK Biobank includes half a million participants recruited between 2006 and 2010. Individuals aged 40–69 years were identified from National Health Service registers and invited to participate. All participants completed a detailed baseline assessment. Linkages have been established, for the whole cohort, with Hospital Episode Statistics (HES), primary care records and death registration data. Furthermore, linkages with Public Health England laboratories permit identification of COVID-19 PCR test results.

Statistical analysis

COVID-19 exposure was defined using disease codes in primary care or HES records, a positive antibody test or a positive PCR test (online supplemental table 1), aligned with UK Biobank recommendations. The first record of COVID-19 in any of the linked sources was assigned the index time. We excluded cases with <30 days follow-up from the matched analysis. Each COVID-19-infected participant was propensity score-matched to two controls with no record of COVID-19, using nearest neighbours matching and with the date of COVID-19 infection being the index date for the matched controls. The following propensity score variables were included: age, sex, Townsend score (deprivation), body mass index, ethnicity, diabetes, prevalent ischaemic heart disease (IHD), smoking, hypertension, high cholesterol. As the COVID-19 exposure variable is time-dependent, propensity scores were calculated using parameter estimates from a Cox regression model. After matching, all covariates had a standardised difference of <0.012 indicating good balance between the exposed and unexposed groups.

We included the following incident CVD outcomes identified from HES and death registration data (online supplemental table 2): myocardial infarction (MI), stroke, heart failure, atrial fibrillation (AF), venous thromboembolism (VTE), pericarditis, all-cause mortality, CVD mortality, IHD mortality. Participants with record of the outcome of interest at the index time were excluded from the analysis for that outcome.

Participants were followed until the first episode of a specific outcome, death or the end of follow-up. The censor date was 30 March 2021 giving, on average, 141 days (range 32–395) of prospective follow-up. The study includes the two first waves of COVID-19 in the UK. Details of the viral variants occurring during this period are reported elsewhere. Vaccination was introduced from December 2020 onwards.

Cox proportional hazard regression was used to estimate association of COVID-19 with incident cardiovascular outcomes reporting HR, 95% CIs and p values. We report associations for the whole sample and by hospitalisation status (non-hospitalised, primary hospital diagnosis, secondary hospital diagnosis). For end points other than all-cause mortality, we looked at cause-specific hazard with death from other causes considered as a competing risk. We accounted for matching by fitting a model stratified on the matched case-control set.

We assessed whether the cardiovascular associations of COVID-19 exposure reduced over time by splitting the data at failure times and fitting an interaction between COVID-19 exposure and time (online supplemental table 3). Inclusion of COVID-19 exposure reduced over time by splitting the data at failure times and fitting an interaction between COVID-19 exposure and time (online supplemental table 3). Inclusion of COVID-19 exposure reduced over time by splitting the data at failure times and fitting an interaction between COVID-19 exposure and time (online supplemental table 3). Inclusion of COVID-19 exposure reduced over time by splitting the data at failure times and fitting an interaction between COVID-19 exposure and time (online supplemental table 3).

Table 1  Baseline* participant characteristics

<table>
<thead>
<tr>
<th></th>
<th>All n=471,227</th>
<th>Whole UK Biobank</th>
<th>Non-COVID-19 n=452,663</th>
<th>Matched cohort</th>
<th>COVID-19 cases n=17,871</th>
<th>Matched controls n=35,742</th>
</tr>
</thead>
<tbody>
<tr>
<td>Men, n (%)</td>
<td>210,730 (44.7%)</td>
<td>8743 (47.1%)</td>
<td>201,987 (44.6%)</td>
<td>8409 (47%)</td>
<td>16,813 (47%)</td>
<td>18,929 (53%)</td>
</tr>
<tr>
<td>Women, n (%)</td>
<td>260,496 (55.3%)</td>
<td>9283 (52.9%)</td>
<td>250,675 (55.4%)</td>
<td>9462 (53%)</td>
<td>19,829 (53%)</td>
<td>18,929 (53%)</td>
</tr>
<tr>
<td>Age on 1 March 2020, median (IQR)</td>
<td>69 (58, 73)</td>
<td>65 (69, 72)</td>
<td>65 (65, 73)</td>
<td>65 (65, 73)</td>
<td>65 (65, 73)</td>
<td>65 (65, 73)</td>
</tr>
<tr>
<td>BMI, median (IQR)</td>
<td>26.7 (24.1, 29.9)</td>
<td>27.6 (24.8, 30.9)</td>
<td>27.6 (24.1, 29.8)</td>
<td>27.5 (24.8, 30.9)</td>
<td>27.4 (24.6, 30.9)</td>
<td>27.4 (24.6, 30.9)</td>
</tr>
<tr>
<td>BAME</td>
<td>25.875 (5.5%)</td>
<td>1838 (10.0%)</td>
<td>2037 (5.3%)</td>
<td>1752 (9.8%)</td>
<td>3395 (9.5%)</td>
<td>3395 (9.5%)</td>
</tr>
<tr>
<td>Diabetes</td>
<td>34.039 (7.2%)</td>
<td>1920 (10.3%)</td>
<td>3211 (7.1%)</td>
<td>1835 (10.3%)</td>
<td>3663 (10.3%)</td>
<td>3663 (10.3%)</td>
</tr>
<tr>
<td>Prevalent IHD</td>
<td>48.452 (10.3%)</td>
<td>2275 (12.3%)</td>
<td>4617 (10.2%)</td>
<td>2184 (12.2%)</td>
<td>4398 (12.3%)</td>
<td>4398 (12.3%)</td>
</tr>
<tr>
<td>Prevalent AF</td>
<td>26.633 (5.7%)</td>
<td>1273 (6.9%)</td>
<td>2536 (5.6%)</td>
<td>1420 (8.0%)</td>
<td>1911 (5.4%)</td>
<td>1911 (5.4%)</td>
</tr>
<tr>
<td>Prevalent HF</td>
<td>10.260 (2.2%)</td>
<td>662 (3.6%)</td>
<td>9598 (2.1%)</td>
<td>805 (4.5%)</td>
<td>856 (2.4%)</td>
<td>856 (2.4%)</td>
</tr>
<tr>
<td>Current smoking</td>
<td>48.994 (10.0%)</td>
<td>2162 (11.7%)</td>
<td>4488 (9.9%)</td>
<td>2096 (11.7%)</td>
<td>4172 (11.7%)</td>
<td>4172 (11.7%)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>157.538 (33.4%)</td>
<td>6505 (35.0%)</td>
<td>15106 (33.4%)</td>
<td>6241 (34.9%)</td>
<td>12474 (34.9%)</td>
<td>12474 (34.9%)</td>
</tr>
<tr>
<td>High cholesterol</td>
<td>83.359 (17.7%)</td>
<td>3475 (18.7%)</td>
<td>80120 (17.7%)</td>
<td>3336 (18.7%)</td>
<td>6689 (18.7%)</td>
<td>6689 (18.7%)</td>
</tr>
<tr>
<td>Townsend score, median (IQR)</td>
<td>−2.17 (−3.66, 0.49)</td>
<td>−1.46 (−3.27, 1.63)</td>
<td>−2.19 (−3.67, 0.43)</td>
<td>−1.48 (−3.27, 1.61)</td>
<td>−1.50 (−3.32, 1.58)</td>
<td>−1.50 (−3.32, 1.58)</td>
</tr>
</tbody>
</table>

*Age, diabetes, prevalent IHD and hypertension in March 2020.

AF, atrial fibrillation; BAME, black Asian and minority ethnic; BMI, body mass index; CVD, cardiovascular disease; HF, heart failure; IHD, ischaemic heart disease;
status and time at risk. Where there was evidence of a time interaction, effects were calculated for events within and after 30 days of infection. We examined associations for the whole sample and by hospitalisation status (none, primary, secondary).

We also conducted sensitivity analysis based on the whole UK Biobank population, with COVID-19 exposure fitted as a time-varying covariate in Cox models (online supplementary figure 1). Variables used in the propensity matching were fitted as covariates. COVID-19 status was assessed by fitting a binary variable and a categorical variable with four levels (unexposed, non-hospitalised, primary hospital diagnosis, secondary hospital diagnosis). Interaction between COVID-19 status and time at risk was used to assess changes in effect sizes over the course of the pandemic. Where significant interaction was found, we calculated effects in the first and second halves of the analysis period. To consider possible selection bias in our hospitalisation variable, we conducted further sensitivity analyses treating hospitalisation as a time-dependent variable so that CVD events occurring before or on the day of admission would be treated as non-hospitalised for COVID-19.

**RESULTS**

**Baseline characteristics**

We identified 20,505 participants with record of COVID-19 infection (figure 1). Of these, 17,871 were successfully
Cardiac risk factors and prevention

Table 3  Associations of COVID-19 case-control status with incident events

<table>
<thead>
<tr>
<th>Incident diseases</th>
<th>All case-control sets n=17 871*</th>
<th>Cases with no hospital admission record n=14 304</th>
<th>Cases hospitalised with primary COVID-19 diagnosis n=2701</th>
<th>Cases hospitalised with secondary COVID-19 diagnosis n=866</th>
</tr>
</thead>
<tbody>
<tr>
<td>MI</td>
<td>1.82 (1.12 to 2.96) P=0.015</td>
<td>0.19 (0.06 to 0.65) P=0.008</td>
<td>9.9 (3.36 to 29.1) P&lt;0.0001</td>
<td>22.2 (8.42 to 71.3) P=0.003</td>
</tr>
<tr>
<td>Stroke</td>
<td>4.15 (2.34 to 6.78) P&lt;0.0001</td>
<td>1.71 (0.86 to 3.63) P=0.12</td>
<td>17.5 (5.26 to 57.9) P&lt;0.0001</td>
<td>4.54 (1.55 to 13.33) P=0.006</td>
</tr>
<tr>
<td>Heart failure</td>
<td>5.6 (4.05 to 7.87) P&lt;0.0001</td>
<td>0.85 (0.45 to 1.61) P=0.63</td>
<td>21.6 (10.9 to 42.9) P&lt;0.0001</td>
<td>13.1 (5.06 to 33.8) P&lt;0.0001</td>
</tr>
<tr>
<td>AF</td>
<td>5.25 (3.98 to 6.93) P&lt;0.0001</td>
<td>1.03 (0.63 to 1.69) P=0.90</td>
<td>14.9 (9.34 to 23.8) P&lt;0.0001</td>
<td>29.3 (6.94 to 124) P&lt;0.0001</td>
</tr>
<tr>
<td>VTE</td>
<td>13.2 (8.75 to 19.9) P&lt;0.0001</td>
<td>2.74 (1.38 to 5.45) P=0.004</td>
<td>27.6 (14.5 to 52.3) P&lt;0.0001</td>
<td>23.1 (5.42 to 98.4) P&lt;0.0001</td>
</tr>
<tr>
<td>Pericarditis</td>
<td>8.21 (3.38 to 20.00) P&lt;0.0001</td>
<td>0.68 (0.07 to 6.48) P=0.74</td>
<td>13.6 (4.06 to 45.8) P&lt;0.0001</td>
<td>–</td>
</tr>
</tbody>
</table>

Mortality

<table>
<thead>
<tr>
<th>Mortality</th>
<th>All-case control sets n=17 871*</th>
<th>Cases with no hospital admission record n=14 304</th>
<th>Cases hospitalised with primary COVID-19 diagnosis n=2701</th>
<th>Cases hospitalised with secondary COVID-19 diagnosis n=866</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause</td>
<td>35.47 (28.24 to 44.55) P&lt;0.0001</td>
<td>10.23 (7.63 to 13.70) P&lt;0.0001</td>
<td>118.01 (73.32 to 189.95) P&lt;0.0001</td>
<td>63.97 (30.14 to 135.77) P&lt;0.0001</td>
</tr>
<tr>
<td>CVD</td>
<td>5.48 (3.24 to 9.29) P&lt;0.0001</td>
<td>2.02 (0.93 to 4.34) P=0.073</td>
<td>8.76 (2.51 to 30.5) P=0.001</td>
<td>14.6 (4.37 to 48.8) P&lt;0.0001</td>
</tr>
<tr>
<td>IHD</td>
<td>4.23 (2.16 to 8.67) P&lt;0.0001</td>
<td>1.00 (0.34 to 2.93) P=0.99</td>
<td>14.1 (1.73 to 113.8) P=0.013</td>
<td>23.7 (3.09 to 182) P=0.002</td>
</tr>
</tbody>
</table>

*Sample sizes indicate the number of cases; the analysis sample also includes two controls per case.

AF, atrial fibrillation; CVD, cardiovascular disease; IHD, ischaemic heart disease; MI, myocardial infarction; VTE, venous thromboembolism.

Figure 2  Summary of study design and results. AF, atrial fibrillation; CVD, cardiovascular disease; IHD, ischaemic heart disease; MI, myocardial infarction; VTE, venous thromboembolism. Red bars indicate statistically significant associations (p<0.05).

matched to 35 742 uninfected controls. Compared with the whole UK Biobank cohort, the cases included slightly more men, were less affluent and had poorer cardiometabolic health (table 1). After matching, the cases and controls were well-balanced on these variables.

Most participants with past COVID-19 were not hospitalised (80.0%, n=14 304). Among the 20.0% (35 742) of cases recorded in hospital, 75.7% (2701) were primary COVID-19 hospitalisations, while 24.3% (866) had COVID-19 recorded as a secondary diagnosis.

Observed events

We observed at least one incident event in 9.0% (1616) of cases and 0.7% (241) of controls (table 2). Among the cases, 3.0% (534) developed at least one of the incident CVDs considered, compared with 0.5% (180) in the controls.

Incident CVDs occurred markedly more commonly in hospitalised cases than in controls. The top three most common incident CVDs among the cases were incident AF, VTE and heart failure. The highest rates of these conditions were observed in participants with a record of primary COVID-19 hospitalisation. In those without record of hospitalisation, there were less marked differences in rates of incident CVDs between cases and controls, but with greater rates of incident stroke, AF and VTE among cases.

A total of 7.3% (1296) of the cases died compared with 0.2% (85) in the controls. Those with primary COVID-19 hospitalisation had the highest rates of death (table 2). There were higher rates of CVD and IHD death in cases compared with controls; this was more marked in individuals with a record of hospitalisation. Individuals admitted with COVID-19 as a secondary diagnosis had the highest rates of death due to CVD and IHD (table 2).

Non-hospitalised participants with COVID-19

Compared with matched uninfected controls, non-hospitalised participants with COVID-19 (n=14 304) had over 2.7-fold greater risk of incident VTE (HR 2.7 (95% CI 1.4 to 5.5); p=0.004) and over 10-fold greater risk of all-cause death (HR 10.2 (95% CI 7.6 to 13.7); p<0.0001).
Cardiac risk factors and prevention

There was no significant association with risk of the other outcomes, with the exception of incident MI, which was significantly lower than in controls (table 3, figure 2).

**Participants with primary COVID-19 hospitalisation**

Individuals with record of primary COVID-19 hospitalisation (n=2701) had significantly increased risk of all outcomes considered (table 3, figure 2). The largest effect sizes were observed with incident VTE (HR 27.6 (95% CI 14.5 to 52.3); p<0.0001), heart failure (HR 21.6 (95% CI 10.9 to 42.9); p<0.0001) and stroke (HR 17.5 (95% CI 5.3 to 57.9); p<0.0001). The risk of incident AF was increased by almost 15-fold, pericarditis by near 14-fold and MI by almost 10-fold (table 3).

The risk of all-cause death was increased by 118-fold (HR 118.0 (95% CI 73.32 to 190.0); p<0.0001), primary CVD death by near 9-fold (HR 8.8 (95% CI 2.5 to 3.5); p=0.001) and IHD death by over 14-fold (HR 14.1 (95% CI 1.7 to 113.8); p=0.013).

**Participants with secondary COVID-19 hospitalisation**

Participants with secondary COVID-19 hospitalisation (n=866) had increased risk of all incident outcomes compared with uninfected controls (table 3). Their risk of all-cause death was less augmented than in those with primary COVID-19 hospitalisation, while their risk of death due to CVD or IHD was higher. Similarly, the risk of incident MI and AF was increased.

---

Figure 3  Histograms of event time for all incident outcomes. Blue bars represent incident events in COVID-19 cases, while the red bars indicate those in matched controls. AF, atrial fibrillation; CVD, cardiovascular disease; HF, heart failure; IHD, ischaemic heart disease; MI, myocardial infarction; VTE, venous thromboembolism.
to a greater extent than in those with primary COVID-19 hospitalisation. While the risk of incident heart failure, stroke and VTE were increased compared with controls, the risk of these conditions was less augmented than in those with a primary COVID-19 admission. There were too few pericarditis cases in this subset for assessment of associations. The most common primary reasons for admission in this subset are presented in online supplemental table 3.

### Modification of risk with time

We considered whether the risk of incident events varied with time from COVID-19 diagnosis. Most events occurred in the early postinfection period, typically within 30 days of infection (figure 3). There was evidence of significant interaction with time for heart failure, AF, VTE, pericarditis and all-cause death outcomes (table 4). For these events, we ran separate models stratified by time from COVID-19 status (within 30 days and after 30 days to capture the early postinfection period). The increased risk of these outcomes in the cases remained statistically significant across both time strata, but with smaller effect sizes beyond the initial 30-day period (table 4).

### Sensitivity analysis

We ran a sensitivity analysis using the entire UK Biobank cohort (n=471,227 participants) alive on 1 March 2020 with inclusion of COVID-19 as a time-varying exposure (online supplemental figure 1). Overall, the pattern of associations was similar to the matched analysis, but with smaller effects for most outcomes in the primary COVID-19 hospitalisation subset (online supplemental table 4). There was significant interaction with time for all outcomes except MI and IHD death, with effect sizes decreasing with increasing time from March 2020 (online supplemental table 5). When treating hospital admission as a time-dependent variable, the effect of COVID-19 on MI was no longer significant (online supplemental table 6).

### DISCUSSION

#### Summary of findings

We studied 17,871 UK Biobank participants with exposure to COVID-19 from 1 March 2020 to 1 March 2021 and 35,742 propensity score-matched uninfected controls, considering the risk of a range of incident CVD and mortality outcomes. Individuals with past COVID-19 exposure had greater risk of incident CVDs and mortality, compared with matched uninfected controls.

Participants who were hospitalised with COVID-19 had increased risk of all incident outcomes considered (MI, stroke, heart failure, AF, VTE, pericarditis, all-cause death, CVD death, IHD death), independent of baseline demographic and cardiometabolic factors. Non-hospitalised participants with COVID-19 had significantly greater risk of incident VTE and all-cause mortality, but not of other outcomes. Cardiovascular risks were greatest in the first 30 days after infection but remained higher than controls even after this period.

### Comparison with existing work

We found significantly increased risk of VTE in both hospitalised and non-hospitalised cases, which remained elevated throughout the entire follow-up period. Our observations are broadly consistent with self-controlled case series analyses from Scotland, Sweden, a retrospective cohort study from the USA and a large prospective cohort study from the USA. Furthermore, a recent analysis of almost 1 million COVID-19 cases across four European nations demonstrated venous and arterial thrombosis in both hospitalised and non-hospitalised cases.

Currently, the National Institute of Health and Care Excellence recommends prophylactic low molecular weight heparin for VTE prevention in hospitalised patients with COVID-19 and in patients who would otherwise be admitted to hospital (eg, hospital at home) for a minimum of 7 days. These recommendations are consistent with those of the British Thoracic Society and the American Society of Hematology. Our results indicate that the risk of VTE is also increased in non-hospitalised individuals. Overall, available evidence supports a distinct mechanistic role for COVID-19 in driving higher VTE rates which occurs across disease severities and extends beyond the early postinfection phase.

In our study, non-hospitalised individuals with mild COVID-19 had increased risk of VTE, but not of any other cardiovascular outcome. In contrast, a recent prospective analysis of US data by Xie et al reports increased risk of a range of cardiovascular outcomes across all disease severities. There are important differences in baseline health status (eg, obesity) and healthcare systems of the UK and the US populations, which may influence both occurrence and recording of cardiovascular outcomes. Furthermore, the UK Biobank cohort is on average healthier than the general UK population, which may protect against increased cardiovascular risk from mild COVID-19. Another possibility is that barriers to healthcare access in the US population have led to delays in seeking medical attention for non-acute cardiac symptoms (eg, stable angina) leading to greater risk of presentation with acute events (eg, acute MI). These observations underscore the need for evaluation of long-term cardiovascular risk in individuals with mild COVID-19 across independent cohorts and for assessment of factors which may modify disease susceptibility.

We observed increased risk of incident MI and stroke in participants hospitalised with COVID-19. These observations are consistent with retrospective analysis of a cohort from Sweden, and prospective analyses from Denmark and the USA. In a retrospective cohort study, Merkler et al demonstrate increased risk of ischaemic stroke in patients hospitalised with COVID-19 compared to those with influenza, indicating a
distinct association between COVID-19 and this outcome. The potential underlying mechanisms include vascular cell involvement, coagulopathy and cytokine-mediated plaque destabilisation.\(^{18}\) We additionally observed increased rates of incident AF, heart failure and pericarditis among hospitalised COVID-19 cases. There is little data on these outcomes in existing work, but our findings are broadly in keeping with available research.\(^{2,3}\)

In our main analysis, we found an unexpected association of COVID-19 with lower risk of incident MI in the non-hospitalised subset. It is likely that this finding is a result of selection bias. Individuals who develop mild COVID-19 in the community, but have an MI very soon after would be admitted to hospital and have COVID-19 recorded as a secondary diagnosis. This means that within the non-hospitalised cases we only count events that occur sufficiently separate from the onset of infection, for COVID-19 to not be recorded as a hospital diagnosis. Whereas for their controls, we count events occurring at any time. In effect, the controls have greater time at risk. Indeed, sensitivity analysis using hospitalisation as a time-dependent variable did not show a significant effect of COVID-19 on MI before hospitalisation. In this analysis, we classified individuals whose CVD event was before or on the day of hospitalisation as non-hospitalised, while events after the day of admission was treated as hospitalised. Future studies should be alert to such potential sources of bias, which may produce spurious associations.

Our study is the first to prospectively examine risk of incident primary cardiovascular death in the setting of COVID-19. We observed increased risk of CVD death and IHD death in participants hospitalised with COVID-19. Notably, while the risk of CVD and IHD mortality was significantly elevated in participants with primary COVID-19 hospitalisation, these events were also markedly greater in individuals with COVID-19 as a secondary diagnosis, which likely relate to their primary admission indication rather than COVID-19.

The long-term sequelae of past COVID-19 exposure is emerging as a dominant public health concern. Our findings highlight the increased cardiovascular risk of individuals with past infection, which are likely to be greater in countries with limited access to vaccination and thus greater population exposure to COVID-19. Furthermore, the long-term cardiovascular consequences reported in our study may be relevant in the context of future pandemics of similar viral infections.

Clinical implications

Our findings indicate increased risk of cardiovascular outcomes following COVID-19, particularly in those requiring hospitalisation. Although most events occur in the early postinfection period, the risk remains augmented for a prolonged period thereafter. Greater attention to management of cardiovascular risk and low threshold for cardiovascular investigations of patients exposed to COVID-19 are important in prevention and timely treatment of cardiovascular events. Further research is required to delineate the period over which the augmented cardiovascular risk persists. Furthermore, more granular analysis of factors which may alter CVD susceptibility following COVID-19 are warranted. The high incidence of VTE in both hospitalised and non-hospitalised cohorts is also concerning. Numerous clinical trials\(^{19,20}\) are currently underway to evaluate the role of prolonged prophylactic anticoagulation in patients post-COVID-19 and should provide some long-awaited answers on the benefits of prolonged anticoagulation in this population.

Strengths and limitations

The large well-characterised sample available through the UK Biobank and extensive health record linkages permitted reliable identification of COVID-19 cases and incident events and creation of a well-balanced matched comparator cohort. We cannot exclude residual confounding from comorbidities not considered in our matching approach (eg, renal disease, cancer). However, given the low prevalence of such factors in the UK Biobank, their omission is unlikely to substantially influence the observed associations. Furthermore, we did not consider the influence of cardiovascular medications, such as statins or ACE inhibitors. Given the significant healthy participant effect in the UK Biobank,\(^{13}\) it is possible that our sample was relatively protected from adverse cardiovascular outcomes and this may have resulted in underestimation of risk. Our analysis also highlights the potential for collider bias in COVID-19 studies, which, by nature, select on testing or hospitalisation. It is important that future researchers are alert to such potential sources of bias and undertake dedicated analyses to evaluate and mitigate such factors. We observed significant time-varying nature of risk in our analysis; it is possible that risk of cardiovascular events is further reduced with longer follow-up periods. Our analysis does not consider other potential modifying factors such as the impact of vaccination, new variants of concern or multiple infection exposures. Such analyses are increasingly relevant as public health approaches to handling of the pandemic evolve.

CONCLUSIONS

In this prospective analysis of 17 871 UK Biobank participants with past COVID-19, we observed increased risk of incident CVD and mortality events in cases compared with uninfected controls, independent of shared demographic and cardiometabolic factors. Overall, our results indicate that while COVID-19 exposure is associated with increased risk of incident adverse cardiovascular events, such risks are almost entirely confined to those with disease requiring hospitalisation and highest in the early (first 30 days) postinfection period.

Author affiliations

1 William Harvey Research Institute, NIHR Barts Biomedical Research Centre, Queen Mary University of London, London, UK
2 Barts Heart Centre, St Bartholomew’s Hospital, Barts Health NHS Trust, London, UK
3 Division of Cardiovascular Medicine, Radcliffe Department of Medicine, National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford, Oxford, UK
4 MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, UK
5 NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK
6 Health Data Research UK, London, UK
7 Alan Turing Institute, London, UK

Twitter Zahra Raisi-Estabragh @zahra_raisi and Betty Raman @BR_CMR

Acknowledgements This study was conducted using the UK Biobank resource under access application 2964.

Contributors ZR-E and SEP conceptualised the work. ZR-E and JC designed the statistical analysis plan. JC led on the data analysis. AS contributed to the data analysis. AML led the data curation and management. ZRE and JC wrote the manuscript. SEP provided overall supervision for the work. BR, NH and SN provided critical review of the work. All coauthors read and approved the final version of the manuscript. ZR-E and SEP are responsible for the overall content and are guarantors of the work.

Funding ZR-E recognises the National Institute for Health Research (NIHR) Integrated Academic Academic Training programme which supports her Academic Clinical Lectureship post and was also supported by British Heart Foundation Clinical Research Training Fellowship No. FS/17/81/33318. AS was supported by a British Heart Foundation project grant (PG/21/10619). BR is funded by BHF Oxford CRE (RE/18/3/34214). Barts Charity (G-002346) contributed to fees required to access
UK Biobank data (access application #2964). SEP acknowledges support from the NIHR Biomedical Research Centre at Barts. SEP has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no 825903 (eucANShare project). SEP acknowledges support from the “SmartHeart” EPSRC programme grant (www.nhr.ac.uk; EP/P001009/1). SN is supported by the Oxford NIHR Biomedical Research Centre (LS-BRC-1215-20008) and the Oxford BHF Centre of Research Excellence. This project was enabled through access to the Medical Research Council (MRC) eMedLab Medical Bioinformatics infrastructure (www.mrc.ac.uk; MR/L016311/1). NCH acknowledges support from MRC (MC_PC_21003; MC_PC_21001) and NIHR Southampton Biomedical Research Centre. This work was supported by Health Data Research UK, an initiative funded by UK Research and Innovation, Department of Health and Social Care (England) and the devolved administrations, and leading medical research charities. The funders provided support in the form of salaries for authors as detailed above.

Disclaimer The funders did not have any role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.

Competing interests SEP provides consultancy to Cardiovascular Imaging, Calgary, Alberta, Canada. BR has consulted for Axcella Therapeutics. The remaining authors have nothing to disclose.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval This study was covered by the ethical approval for UK Biobank studies from the NHS National Research Ethics Service on 17 June 2011 (Ref 11/ NW/0382) and extended on 18 June 2021 (Ref 21/NW/0157) with written informed consent obtained from all participants. This study complies with the Declaration of Helsinki.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data may be obtained from a third party and are not publicly available. The UK Biobank will make the source data available to all bona fide researchers for all types of health-related research that is in the public interest, without preferential or exclusive access for any persons. All researchers will be subject to the same application process and approval criteria as specified by UK Biobank. For more details on the access procedure, see the UK Biobank website: http://www.ukbiobank.ac.uk/register-apply http://www.ukbiobank.ac.uk/register-apply.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

REFERENCES

4. UK Biobank Coordinating Centre. UK Biobank: protocol for a large-scale prospective epidemiological resource. UKBB-PROT-09-06 (main phase), 2007; https://www.ukbiobank.ac.uk/media/gnye/h2q/study-rationale.pdf.

ORCID IDs

Zahra Raisi-Estabragh http://orcid.org/0000-0002-7757-5465
Steffen E. Petersen http://orcid.org/0000-0003-4622-5160